Building on our success with UDENYCA^® (pegfilgrastim-cbqv), we are now expanding our mission to immuno-oncology with Junshi Biosciences’ novel anti-PD-1 antibody, toripalimab.

Coherus is dedicated to expanding patient access to important medicines and delivering significant savings to the U.S. healthcare system.